Investigating the clinical utility of the percent of positive prostate biopsies in predicting PSA outcome following local therapy for patients with clinically localized prostate cancer

A. V. D'Amico, R. Whittington, S. B. Malkowicz, D. Schultz, B. Silver, L. Henry, M. Hurwitz, I. Kaplan, C. J. Beard, J. E. Tomaszewski, A. A. Renshaw, A. Wein, J. P. Richie

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

The clinical utility of the percent of positive prostate biopsies in predicting prostate-specific antigen (PSA) outcome following radical prostatectomy (RP), or external beam radiation therapy (RT), for men with PSA detected, or clinically palpable prostate cancer was investigated. After accounting for the established prognostic significance of the PSA level, biopsy Gleason score and the clinical T-stage, the percent of positive prostate biopsies added clinically significant information regarding time to PSA failure following RP. These findings were validated in the intermediate risk patients using an independent surgical and radiation data set.

Original languageEnglish (US)
Pages (from-to)259-264
Number of pages6
JournalProstate Cancer and Prostatic Diseases
Volume3
Issue number4
DOIs
StatePublished - 2000

All Science Journal Classification (ASJC) codes

  • Oncology
  • Urology
  • Cancer Research

Fingerprint Dive into the research topics of 'Investigating the clinical utility of the percent of positive prostate biopsies in predicting PSA outcome following local therapy for patients with clinically localized prostate cancer'. Together they form a unique fingerprint.

  • Cite this

    D'Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D., Silver, B., Henry, L., Hurwitz, M., Kaplan, I., Beard, C. J., Tomaszewski, J. E., Renshaw, A. A., Wein, A., & Richie, J. P. (2000). Investigating the clinical utility of the percent of positive prostate biopsies in predicting PSA outcome following local therapy for patients with clinically localized prostate cancer. Prostate Cancer and Prostatic Diseases, 3(4), 259-264. https://doi.org/10.1038/sj.pcan.4500413